Form 4 for RLAY Relay Therapeutics, Inc.
Accepted 2021-11-16 00:00:00 ET · period of report 2021-11-15 · accession 0001209191-21-064872 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2021-11-16 | 2021-11-15 | RLAY | Adams Brian | GC | S - Sale+OE | $35.42 | -6,500 | 25.3K | -20% | -$230.2K |
| D | 2021-11-16 | 2021-11-15 | RLAY | Adams Brian | GC | M - OptEx | $4.12 | +6,500 | 31.8K | +26% | +$26.8K |
| D | 2021-11-16 | 2021-11-15 | RLAY | Adams Brian | GC | M - OptEx | $0.00 | -6,500 | 140.8K | -4% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-11-15 | S | D | 6,500 | $35.42 | 25,284 | D | — | — | (F3) This transaction was executed in multiple trades at prices ranging from $35.03 to $35.80. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. (F2) Includes 13,887 shares underlying RSUs. |
| 2 | Common | Common Stock | 2021-11-15 | M | A | 6,500 | $4.12 | 31,784 | D | — | — | (F2) Includes 13,887 shares underlying RSUs. |
| 3 | Derivative | Stock Option (Right to Buy) | 2021-11-15 | M | D | 6,500 | $0.00 | 140,786 | D | $4.12 · — to 2028-03-22 | 6,500 Common Stock | (F4) Twenty-five percent (25%) of the shares underlying this option vested on March 19, 2019 and the remainder shall vest in equal quarterly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date. |